Another ViewEPS of $0.69 beat estimates of $0.65; sales of $753M beat estimates of $718.5M. EBITDA of $137.8M beat estimates by 21%. Revenue rose 23%. Backlog is $2.02B, up 30%. The balance sheet has improved with the US IPO and management expects higher earnings as margins improve. There are still some supply chain issues and inflationary pressures, but this was a solid quarter for ATS and the outlook is good. We would consider recent weakness an opportunity to buy/add. (5iResearch)